Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild to- moderate Alzheimer’s disease (BLAZE) - Salloway, S; Honigberg, LA; Cho, W; Ward, M; Friesenhahn, M; Brunsteins, F (Alzheimers Res Ther, 2018)